Towards a Personalized Medicine Approach for HCC

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer death with limited effective treatments.
• Late diagnosis and multidrug resistance hinder current therapeutic options for HCC.
• Existing therapies for HCC, like tyrosine kinase and immune checkpoint blockers, offer limited efficacy.

Purpose of the Study:

• To review current and emerging therapeutic strategies for hepatocellular carcinoma (HCC).
• To explore molecular targets and metabolic network-based approaches for personalized HCC medicine.
• To highlight the potential of novel therapies like microRNA-based treatments for HCC.

Main Methods:

• Integrated genomic profiling to identify common genetic alterations in HCC.
• Genome-scale metabolic modeling to understand cancer-specific metabolism.
• Review of microRNA-based therapeutic strategies, including antagonists and substitution therapy.

Main Results:

• Key genetic alterations in HCC include telomerase reverse transcriptase, CTNNB1, and TP53.
• Metabolic network analysis reveals HCC heterogeneity based on redox response and metabolite utilization.
• MicroRNA-based therapies offer a promising avenue by targeting oncogenic or restoring tumor-suppressor miRNAs.

Conclusions:

• Personalized medicine for HCC can be advanced by understanding metabolic network heterogeneity.
• MicroRNA-based therapies present a novel strategy to overcome limitations in HCC treatment.
• Targeting molecular and metabolic pathways is crucial for developing more effective HCC therapies.